Glenmark confirms Vimpat challenge

Glenmark confirms Vimpat challenge
July 16, 2013

Bill Baton, a partner in the Intellectual Property & Technology and Commercial Litigation practices, is quoted in this article about Glenmark Generics filing Abbreviated New Drug Applications (“ANDA”) to market generic versions of the epilepsy drug Vimpat. Baton explains that provisions in the Hatch-Waxman Act may give Glenmark a period of time to exclusively market its generic versions if it is the first company confirmed to have filed its ANDAs.

However, he said in the article that, “more than one company could be a ‘first filer,’ meaning that more than one generic company may be granted exclusivity.” To read the entire article, click here.